Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGE pro for Chronic Wounds in Epidermolysis Bullosa
NCT03942250Completed
- Sponsor
- Egyptian Atomic Energy Authority
- Start
- Jan 2017
- Primary completion
- Dec 2017
- Modality
- Biologic
- Countries
- 1
01
Overview
Open-label, single-arm trial of Rege-Pro in dystrophic epidermolysis bullosa (DEB) and chronic skin ulcer, sponsored by Egyptian Atomic Energy Authority. Primary endpoints: Lesion area at 6 weeks and Clinical progression signs at 6 weeks. Started Jan 2017; status: completed.
02
Drugs
Rege-Pro
03
Conditions
dystrophic epidermolysis bullosa (DEB)chronic skin ulcer
Beyond the preview
Go deeper on NCT03942250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03942250.